Microbial Nucleic Acid Detector Gets FDA Class II Designation
Published Date: 5/9/2025
Rule
Summary
The FDA is officially putting a special kind of medical device that spots tiny germs in patient samples into a safer, middle-level category called Class II. This change means the device will follow clear safety rules, helping patients get better access to cool new tech without extra red tape. If you make or use these devices, get ready for updated rules that keep things safe and effective, starting now!
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
FISH Microbial Tests Moved to Class II
The FDA is classifying devices that detect and identify microbial nucleic acids by fluorescence in situ hybridization (FISH) in clinical specimens into Class II (special controls). The special controls for this device type will be codified and apply to makers and users of these devices, and the FDA says this step will provide a reasonable assurance of safety and effectiveness.
FDA Says Patient Access to FISH Tests Will Improve
The FDA states that classifying these FISH microbial nucleic acid detection devices into Class II (special controls) will enhance patients' access to beneficial innovative devices by reducing regulatory burdens. The agency says this action provides reasonable assurance of the devices' safety and effectiveness, which is intended to help patient access.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-09767 — Oscar Bobo: Final Debarment Order
Oscar Bobo is officially banned for 5 years from importing any drugs into the U.S. because he repeatedly brought in mislabeled medicines that don’t follow FDA rules. He ignored the chance to defend himself, so the ban started on May 15, 2026. This means no drug imports from him for a while, but he can apply to end the ban anytime if he meets FDA’s conditions.
2026-09448 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; The Real Cost Campaign Outcomes Evaluation Study: Cohort 3
The FDA is asking for approval to collect info for the third group in its Real Cost Campaign, which teaches kids about the dangers of tobacco. This helps the FDA improve its anti-smoking messages and protect young people’s health. Comments on this info collection are open until June 12, 2026, with no new costs for participants.
2026-09543 — Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting
The FDA wants your thoughts on how drug companies report problems after their products hit the market. This affects drug makers and healthcare folks who keep track of side effects. They’re asking for comments by July 13, 2026, to help improve the process without adding extra costs or paperwork.
2026-09544 — Modified Risk Tobacco Product Application: Renewal Applications for VLN® King and VLN® Menthol King, Cigarette Products Submitted by 22nd Century Group Inc.
The FDA is inviting the public to comment on the renewal of special approval for two cigarette products by 22nd Century Group Inc. These products claim to lower health risks compared to regular cigarettes. If approved, the renewal keeps these products on the market with their modified risk status, affecting smokers and the tobacco industry starting May 13, 2026.
2026-09335 — Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Detect and Identify Microorganism Nucleic Acids and Resistance Markers From Patients With Suspected Orthopedic Infection
Hey there! This update is all about a new medical device that helps doctors quickly find germs and their resistance traits in people who might have bone infections. It affects hospitals and labs by officially classifying this device, making it easier and faster to diagnose tough infections. The change kicks in soon, helping patients get the right treatment without delay—and it could save money by avoiding wrong meds!
2026-09368 — Enforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization; Guidance for Industry; Availability
The FDA is setting clear rules for certain new tobacco products like e-cigarettes and nicotine pouches that don’t have official approval yet. Companies selling these products without permission might face enforcement actions starting now, so they need to get authorized or risk penalties. This helps protect public health and keeps the market fair and safe.
Previous / Next Documents
Previous: 2025-08149 — Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Detect Nucleic Acids From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections and Associated Resistance Marker(s)
The FDA is officially classifying a new device that detects germs causing sexually transmitted infections and their resistance markers as a Class II device with special safety rules. This change helps make sure the device is safe and works well, while also making it easier for patients to get access to these important tests. Companies making these devices will follow new guidelines starting now, which could speed up innovation without extra costs.
Next: 2025-08151 — Medical Devices; Hematology and Pathology Devices; Classification of the Coagulation System for the Measurement of Whole Blood Viscoelastic Properties in Perioperative Patients
The FDA is officially classifying a blood clot-checking device used during surgery as a Class II device with special safety rules. This change helps make sure the device is safe and works well, while also making it easier for new, helpful devices to reach patients. Hospitals and device makers should get ready for these new rules, which aim to speed up access without extra costs.